Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Natural Product (NP) Details

General Information of the NP (ID: NP6054)
Name
Selenium
Synonyms
7782-49-2; Se; Selenium; SELENIUM ATOM; Selenium and compounds; Elemental selenium; Selenium elemental; Selenium, elemental; Selen; SELENIUM COMPOUNDS; Selenium dihydride; SELENIUM POWDER; Hydrogen selenide (H2Se); UNII-H6241UJ22B; MFCD00134090; UNII-V91P54KPAM; H6241UJ22B; Vandex; Gray selenium; Selenium alloy; Selenium base; Selenium dust; Selenium, 99+%, powder; Colloidal selenium; Selen [Polish]; Selenium, metallic; Selenium homopolymer; Selenium, colloidal; Caswell No. 732; selenio; Selenium anhydride; Electronic E-2; Selenium metallicum; Selenium, 99.5+%, powder, 200 mesh; CCRIS 4250; HSDB 4493; EINECS 231-957-4; UN2658; EPA Pesticide Chemical Code 072001; Selenium compounds, n.o.s.; CI 77805; Selenium standard solution, for AAS, 1 mg-ml Se in 10% HCl; Selenium and selenium compounds; HSDB 548; C.I. 77805; Selenium, powder; EINECS 231-978-9; Selenium shot, 4N; UN2202; UN3283; ACMC-20ajqt; Dihydrogen monoselenide; selenium (iv) hydride; Selenium hydride (SeH2); 34Se; EC 231-957-4; Selenium, powder, 99+%; Selenium compound, n.o.s.; Hydrogen selenide, anhydrous; Selenium powder, -200 mesh; Selenium powder, -325 mesh; Selenium, p.a., 99.5%; CHEMBL1235891; DTXSID9021261; CHEBI:27568; HSDB 6909; DTXSID20872822; Selenium Nanopowder in aq. media; 8988AF; MFCD00011224; DB11135; Selenium, pellets, < 5mm, >=99.999%; FT-0701285; Selenium ingot/button, ~38mm (1.5in) dia; C01529; Selenium powder [UN2658] [Keep away from food]; Selenium shot, amorphous, 1-5mm (0.04-0.20in); Selenium, foil, 25x25mm, thickness 3mm, 99.95%; Hydrogen selenide, anhydrous [UN2202] [Poison gas]; S008000000; Selenium, plasma standard solution, Specpure, Se 10g/ml; Selenium, shots, 99.99999% (7N), diameter 2-4 mm; Selenium, AAS standard solution, Specpure?, Se 1000?g/ml; Selenium, ingot, 99.9999% diameter 20 mm, length 55 mm; Selenium, pellets, <5 mm, >=99.99% trace metals basis; Selenium, powder, -100 mesh, >=99.5% trace metals basis; Selenium, powder, -100 mesh, 99.99% trace metals basis; Selenium, plasma standard solution, Specpure?, Se 1000?g/ml; Selenium, ingot, 99.99999% (7N), diameter 20 mm, length 55 mm; Selenium, Oil based standard solution, Specpure?, Se 1000?g/g; Selenium, plasma standard solution, Specpure?, Se 10,000?g/ml; Selenium compound, n.o.s. [UN3283] [Poison, Keep away from food]; Selenium, lump, 3 mm max. lump size, weight 100 g, high purity 99.999%; Selenium, lump, 3 mm max. lump size, weight 20 g, high purity 99.999%; Selenium, lump, 3 mm max. lump size, weight 50 g, high purity 99.999%; Selenium, pellets, <5 mm particle size, >=99.999% trace metals basis; Selenium shot, amorphous, 2-6mm (0.08-0.2in), Puratronic(R), 99.999% (metals basis); Selenium, powder, 250 max. part. size (micron), purity 99.95%, weight 100 g; Selenium, powder, 250 max. part. size (micron), weight 50 g, purity 99.95%; Selenium, powder, max. particle size 250 micron, weight 200 g, purity 99.95%; Se0; Selenium atomic spectroscopy standard concentrate 1.00 g Se, 1.00 g/L, for 1L standard solution, analytical standard
    Click to Show/Hide
Disease Thyroid cancer [ICD-11: 2D10] Phase 4 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
Se
PubChem CID
6326970
Canonical SMILES
[Se]
InChI
1S/Se
InChIKey
BUGBHKTXTAQXES-UHFFFAOYSA-N
CAS Number
CAS 7782-49-2
ChEBI ID
CHEBI:27568
Herb ID
HBIN043638
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Docetaxel      Solid tumour/cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Biological
                    Regulation
Induction Cell cycle arrest in G2/M phase
                    In-vitro Model MDA-MB-231 CVCL_0062 Breast adenocarcinoma Homo sapiens
MCF-7 CVCL_0031 Invasive breast carcinoma Homo sapiens
                    Experimental
                    Result(s)
The combination of selenium with docetaxel inhibits cell proliferation through apoptosis and cell arrest in the G2/M phase in MDA-MB-231 breast cancer cells.
          Sulfamethoxazole      Bacterial infection     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model This experiment was carried out on 30 Wistar rats weighing 100-125 g, liver cancer was induced by a carcinogenic dose of 200 mg/kg body weight, I.P. DENA when associated with fasting/refeeding.
                    Experimental
                    Result(s)
Selenium and sulfonamide (sulfamethoxazole) together can possess synergistic chemopreventive action.
          Levothyroxine      Hypo-thyroidism     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [4]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Clinical Trial
                    Experimental
                    Result(s)
Levothyroxine and selenium combination results in improved therapeutic effects than the levothyroxine monotherapy in preventing CLT progression.
          Ionizing radiation      Renal Insufficiency     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [5]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model NCI-H460 CVCL_0459 Lung large cell carcinoma Homo sapiens
NCI-H1299 CVCL_0060 Lung large cell carcinoma Homo sapiens
WI-38 CVCL_0579 Healthy Homo sapiens
                    Experimental
                    Result(s)
Selenium selectively enhanced the radiosensitivity of the tumor cells whereas that of the normal cells was unaffected.
          Doxorubicin      Solid tumour/cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [6]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model T84 CVCL_0555 Colon adenocarcinoma Homo sapiens
Caco-2 CVCL_0025 Colon adenocarcinoma Homo sapiens
Hep-G2 CVCL_0027 Hepatocellular carcinoma Homo sapiens
Rh2 CVCL_A460 Embryonal rhabdomyosarcoma Homo sapiens
MCF-7 CVCL_0031 Invasive breast carcinoma Homo sapiens
SK-BR-3 CVCL_0033 Breast adenocarcinoma Homo sapiens
BCaP-37 CVCL_0164 Breast cancer Homo sapiens
LNCaP CVCL_0395 Prostate carcinoma Homo sapiens
PC-3 CVCL_0035 Prostate carcinoma Homo sapiens
MCF-10 Breast cancer Homo sapiens
                    Experimental
                    Result(s)
Supplementation of Selenium enhanced chemotherapeutic effect of Taxol and Doxorubicin in these cells beyond that seen with the chemotherapeutic drugs used alone.
    β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP
          Cis-diamminedichloroplatinum      Ovarian cancer     Click to Show/Hide the Molecular Data of This Drug
                 Decreasing Adverse Drug Reaction     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [7]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model MC B6-1 cells dissociated from solid tumor Fibrosarcoma Rattus norvegicus
                    In-vivo Model The MC B6-1 fibrosarcoma was originally induced by s.c.injection of 2 mg of methylcholanthrene in a female C57BL/6 mouse and serially transplanted in syngeneic mice.
                    Experimental
                    Result(s)
The addition of selenium decreases the nephrotoxicity of cis-DDP.
References
Reference 1 ClinicalTrials.gov (NCT04683575) Clinical Study on the Effect of Selenium Yeast Capsule on Prognosis of Differentiated Thyroid Carcinoma
Reference 2 Effects of combination therapy of docetaxel with selenium on the human breast cancer cell lines MDA-MB-231 and MCF-7. Ann Surg Treat Res. 2015 Feb;88(2):55-62.
Reference 3 Combination of sulfamethoxazole and selenium in anticancer therapy: a novel approach. Mol Cell Biochem. 2013 Dec;384(1-2):279-85.
Reference 4 Levothyroxine monotherapy versus levothyroxine and selenium combination therapy in chronic lymphocytic thyroiditis. J Endocrinol Invest. 2017 Nov;40(11):1243-1250.
Reference 5 Enhanced lung cancer cell killing by the combination of selenium and ionizing radiation. Oncol Rep. 2007 Jan;17(1):209-16.
Reference 6 Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. Anticancer Res. May-Jun 2000;20(3A):1391-414.
Reference 7 Effect of selenium in combination with cis-diamminedichloroplatinum(II) in the treatment of murine fibrosarcoma. Cancer Res. 1984 Jul;44(7):2864-8.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China